Last reviewed 2026-05-14 · How we verify

Leader Antacid

Merck Sharp & Dohme LLC · FDA-approved active Small molecule Quality 0/100

Leader Antacid is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently FDA-approved.

At a glance

Generic name	Leader Antacid
Sponsor	Merck Sharp & Dohme LLC
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Effect of Antacids on the Pharmacokinetics (PK) of Raltegravir in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-824) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Leader Antacid CI brief — competitive landscape report
Leader Antacid updates RSS · CI watch RSS
Merck Sharp & Dohme LLC portfolio CI

Frequently asked questions about Leader Antacid

What is Leader Antacid?

Leader Antacid is a Small molecule drug developed by Merck Sharp & Dohme LLC.

Who makes Leader Antacid?

Leader Antacid is developed and marketed by Merck Sharp & Dohme LLC (see full Merck Sharp & Dohme LLC pipeline at /company/merck).

What development phase is Leader Antacid in?

Leader Antacid is FDA-approved (marketed).

Manufacturer: Merck Sharp & Dohme LLC — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing